Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Publication
- Publication Type
- File Type
Articles 1 - 9 of 9
Full-Text Articles in Diseases
Current And Novel Neuroregenerative Therapies, Arrin Brooks
Current And Novel Neuroregenerative Therapies, Arrin Brooks
Theses, Dissertations and Capstones
Underlying the physical and cognitive deficits consequent of many neuropathologies is one common factor, the loss of neurons. While neurodegenerative diseases, stroke, and traumatic brain injury arise from a variety of etiologies, they all ultimately result in injury and/or death of neuronal cells and concomitant functional deficits. In the present work we primarily focus on current and potential treatments for localized lesions, particularly those in the striatum of Parkinson’s disease (PD) or the cortex as in stroke. First, we discuss a new surgical technique for deep brain stimulator (DBS) placement, as DBS is a mainstay treatment for movement disorders including …
The Comparative Efficacy Of Amantadine Vs. Lcig Therapy For The Treatment Of Levodopa-Induced Dyskinesia In Patients With Advanced Parkinson's Disease, Katelynn Timony
The Comparative Efficacy Of Amantadine Vs. Lcig Therapy For The Treatment Of Levodopa-Induced Dyskinesia In Patients With Advanced Parkinson's Disease, Katelynn Timony
Capstone Showcase
Introduction: Though levodopa-carbidopa therapy remains the gold standard of Parkinson’s disease (PD) treatment to this day, patients often experience increased dyskinetic activity as a result of long-term treatment; known as levodopa-induced dyskinesia (LID); the mechanism of which is not completely understood. In this review, the efficacy of two adjunct treatments for LID are compared: 1) the concomitant administration of amantadine, an antiviral medication with antidyskinetic properties; and 2) a new form of levodopa administration in the form of an intestinal gel delivered straight via a device much like an insulin pump.
Methods: Two systematic literature searches of primary, peer-reviewed articles …
Characterization And Personalization Of Botulinum Toxin Type A Therapy For Upper Limb Tremor In Parkinson Disease And Essential Tremor Patients Using Multi-Sensor Kinematic Technology, Olivia Samotus
Electronic Thesis and Dissertation Repository
Tremor commonly affects the upper extremities in essential tremor (ET) and Parkinson disease (PD) patients where many experience functional disability and ultimately seek therapy. As ET and PD tremor features overlap and clinical assessment is challenging due to its highly complex nature, misdiagnosis is common resulting in unsuitable therapies and prognosis. Current treatment options for ET and PD tremor include pharmacotherapy, focal therapy with botulinum toxin type A (BoNT-A) injections, and surgical interventions which provide modest relief of tremor. However, such therapies are commonly associated with significant adverse events and lack long-term efficacy and tolerability. Hence lack of standardized, objective …
An Initial Analysis Of A Long-Term Ketogenic Diet’S Impact On Motor Behavior, Brain Purine Systems, And Nigral Dopamine Neurons In A New Genetic Rodent Model Of Parkinson’S Disease, Jacob Rubin, William H. Church
An Initial Analysis Of A Long-Term Ketogenic Diet’S Impact On Motor Behavior, Brain Purine Systems, And Nigral Dopamine Neurons In A New Genetic Rodent Model Of Parkinson’S Disease, Jacob Rubin, William H. Church
Senior Theses and Projects
A growing body of research suggests that dopaminergic cell death seen in Parkinson’s disease is caused by mitochondrial dysfunction. Oxidative stress, with subsequent generation of reactive oxygen species, is the hallmark biochemical product of mitochondrial dysfunction. The ketogenic diet has been found to enhance mitochondrial energy production, protect against reactive oxygen species-generated cell death, and increase adenosine, a purine that modulates dopamine activity. The current study evaluates the effects of a long-term (5-month) ketogenic diet on behavioral, neurochemical, and neuroanatomical measures in PINK1-KO rats, a new animal model of Parkinson’s disease. Both wild-type and PINK1-KO animals fed a ketogenic diet …
Marijuana Compounds: A Nonconventional Approach To Parkinson’S Disease Therapy, Mariana Babayeva, Haregewein Assefa, Paramita Basu, Sanjeda Chumki, Zvi G. Loewy
Marijuana Compounds: A Nonconventional Approach To Parkinson’S Disease Therapy, Mariana Babayeva, Haregewein Assefa, Paramita Basu, Sanjeda Chumki, Zvi G. Loewy
Touro College of Pharmacy (New York) Publications and Research
Parkinson’s disease (PD), a neurodegenerative disorder, is the second most common neurological illness in United States. Neurologically, it is characterized by the selective degeneration of a unique population of cells, the nigrostriatal dopamine neurons. The current treatment is symptomatic and mainly involves replacement of dopamine deficiency.This therapy improves only motor symptoms of Parkinson’s disease and is associated with a number of adverse effects including dyskinesia. Therefore, there is unmet need for more comprehensive approach in the management of PD. Cannabis and related compounds have created significant research interest as a promising therapy in neurodegenerative and movement disorders. In this review …
Is Deep Brain Stimulation A Viable Treatment For Parkinson’S Disease?, Brocha Gold
Is Deep Brain Stimulation A Viable Treatment For Parkinson’S Disease?, Brocha Gold
The Science Journal of the Lander College of Arts and Sciences
Treatment options for those suffering from Parkinson’s Disease are as diverse as its symptoms. With the advent of modern technology there are new and innovative treatments that are becoming available, such as Deep Brain Stimulation (DBS). Prior to exploring treatment options one must understand the various causes of the disease. Treatment of the various motor and non-motor symptoms can include a combination of medication and surgical therapies. Among surgical interventions DBS is the treatment of choice. It has the fewest side effects and provides the greatest symptomatic relief.
The N-Glycosylation Of Immunoglobulin G As A Novel Biomarker Of Parkinson’S Disease, Alyce Christine Russell
The N-Glycosylation Of Immunoglobulin G As A Novel Biomarker Of Parkinson’S Disease, Alyce Christine Russell
Theses: Doctorates and Masters
For neurodegenerative diseases, interventions during the early stages of the disease, before significant neurodegeneration has occurred, are associated with an increased probability of slowing or halting the disease process. In order to intervene early, it is essential that an accurate diagnosis is obtained and that disease progression can be monitored. This is particularly relevant for Parkinson’s disease (PD; International Classification of Diseases version 10) because significant neurodegeneration has already occurred by the time the clinical motor symptoms are present. Therefore, the development of translatable, high-throughput biomarkers for large scale population screening is a crucial area of research. Of promise are …
Can Healthy Transplanted Tissue Be Used To Restore Motor Function In Patients With Parkinson's Disease?, Aliza Erlbaum
Can Healthy Transplanted Tissue Be Used To Restore Motor Function In Patients With Parkinson's Disease?, Aliza Erlbaum
The Science Journal of the Lander College of Arts and Sciences
Parkinson’s Disease is a condition that disrupts the lives the many people. The disease is characterized by a loss of dopamine producing neurons in the pars compacta of the substantia nigra of the ventral midbrain, and symptoms include a lack of motor control and rigidity in motion. Currently, there are many treatments available to treat patients with Parkinson’s disease. However, each treatment involves many adverse side effects that most wish to avoid. Science is discovering possible innovative, alternative options to treat Parkinson’s disease such as the transplantation of healthy dopaminergic neurons directly into the striatum of the patient. Methods include …
Treatment Options For Parkinson’S Disease, Sara Russ
Treatment Options For Parkinson’S Disease, Sara Russ
The Science Journal of the Lander College of Arts and Sciences
The following is an excerpt from this article: Parkinson’s disease was first described and named Paralysis Agitans in 1817 by British physician James Parkinson (Lieberman 2004). Later on, it took on its current name after Dr. Parkinson. Parkinson’s disease (PD) is a neurological disorder for which the cause is yet to be discovered. Like many other diseases, PD has numerous facets. Throughout all of its different stages, it presents with motor, as well as nonmotor, symptoms (Simuni et al. 2009). Though estimates of people affected by PD are constantly being made, it is difficult to determine a precise and accurate …